San Antonio, TX – May 31, 2023 – LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.
Todd brings nearly 20 years of client services, commercial and clinical operations experience to LumaBridge. His expertise spans multiple therapeutic areas, with a particular emphasis on oncology and ophthalmology. Prior to joining LumaBridge, Todd held various leadership roles in operations and portfolio management with a focus on the biotech customer at PPD, a Thermo Fisher Scientific company. Prior to PPD, he led the Medical Affairs, Global Clinical & Regulatory Operations at Alcon Laboratories. Todd began his career in the clinical research industry in 2004 at Rx Development Resources, the CRO division of Sirion Therapeutics. Todd holds an M.S. in biomedical engineering and a B.S. in chemical engineering, from the University of South Florida.
“We are thrilled to welcome Todd to the LumaBridge team,” said David Boyle, Chief Executive Officer of LumaBridge. “Todd’s extensive experience in the industry will play a pivotal role in driving our next phase of growth as we continue to scale our clinical trial capabilities.”
“I’m honored to be joining LumaBridge at this exciting stage of growth in the company’s evolution,” said Todd Lehman. “I look forward to supporting the continued efforts of our customers in bringing innovative solutions to oncology patients.”
